Skip to navigation Skip to content

Clinical Trial: Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Share

Details
Type of MS: PPMS
Treatment mode of action: To prevent progression
Number of Subjects: 100
Medication: ocrelizumab
Location: California
Institutions: SC3 Research - Pasadena Contact Information
Roxanne Cabading, ext. 799
(626) 250 2070
roxanne.cabading@neurosearch-usa.com

Funding:

F. Hoffmann-La Roche Ltd

Description

This study will evaluate the effectiveness and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression.

Share

© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.